Skip to main content
NIH funding notice RFA-DK-14-008

Reagents for Glucagon and Incretin Research (R43/R44)

Closed on November 24, 2014.

Posted
May 2, 2014
Close date
November 24, 2014
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
3
3 new
Median first-year cost
$224,670
$697,160 in all
Institutions
3
3 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. AVANTGEN, INC.1
  2. CONFOMETRX, INC.1
  3. SILVER LAKE RESEARCH CORPORATION1

Most frequent study sections

  1. Special Emphasis Panel (ZDK1 GRB-7 (M2))3
3 awards under RFA-DK-14-008 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2015Structure-based Drug Discovery for the GLP-1 Receptor1R44DK106942-01Chu, MatthewSun, BingfaCONFOMETRX, INC., CAFirst-year cost $249,003Study section ZDK1
FY2015Developing a highly specific and sensitive glucagon ELISA kit1R43DK106946-01Fan, XiaominAVANTGEN, INC., CAFirst-year cost $224,670Study section ZDK1
FY2015Development of Faster, Lower-Cost, High-Sensitivity Immunoassay for Specific Determination of Glucagon Using EAP-derived Monoclonal Antibodies1R43DK106944-01Geisberg, MarkSILVER LAKE RESEARCH CORPORATION, CAFirst-year cost $223,487Study section ZDK1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.